News

Business Insider12d
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
Nasdaq12d
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) Tuesday said it has resubmitted the Biologics License Application (BLA) for ONS-5010 for the treatment of wet age-related macular degeneration or wet AMD.
How to use Outlook Authentication Check Troubleshooter in Windows 11
If Outlook couldn't authenticate with server and is continuously asking for password, use Outlook Authentication Check ...
Yahoo Finance13d
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that ...
manilatimes13d
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook ...